Search Results for "post traumatic stress disorder"

Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Sep 14^th • 4 mins read

Paulo J. Oliveira, Ana M. Urbano

“Oncometabolism: The switchboard of cancer: An editorial”

Feb 1^st • 1 min read

Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Nov 20^th • 12 mins read

Muneera Al Hussain

Comment on: Oncology research in Saudi Arabia over a 10-year period. A synopsis

Jun 24^th • 3 mins read

Benjamin Gregory Carlisle, Adélaïde Doussau, Jonathan Kimmelman

Patient burden and clinical advances associated with post approval monotherapy cancer drug trials: a retrospective cohort study

Feb 17^th • 7 mins read

Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Jan 7^th • 8 mins read

S.E. Abdullah, E. Oflazoglu, J.C. Soria, M.M. Dar

New Realities of Phase I Clinical Trials in the Era of

Oct 7^th • 5 mins read

Natansh D. Modi, BPharm; Ahmad Y. Abuhelwa, PhD; Ross A. McKinnon, PhD

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration

Jul 28^th • 20 mins read

Robbe Saesen, Georgios Kantidakis, Ann Marinus, Denis Lacombe, Isabelle Huys

How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer

Aug 1^st • 45 mins read

Envision Pharma Group

Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

May 9^th • 5 mins read

Envision Pharma Group

Medical affairs: The power behind redefining commercialization

Aug 2^nd • 3 mins read

Envision Pharma Group

Empowering people to drive medical affairs performance with AI

Aug 14^th • 5 mins read

E Dawn Flick, Howard R Terebelo, Susan Fish, Amani Kitali, Vrinda Mahajan, Melissa Nifenecker, Kristen Sullivan, Paul Thaler, Sarah Ussery, David L Grinblatt

The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research

Jun 7^th • 8 mins read

Shen Lin, Yaping Huang, Liangliang Dong, Meiyue Li, Yahong Wang, Dian Gu, Wei Wu, Dongni Nian, Shaohong Luo, Xiaoting Huang, Xiongwei Xu and Xiuhua Weng

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks

Feb 23^rd • 9 mins read

Garth W. Strohbehn, MD, MPhil, Allen S. Lichter, MD and Mark J. Ratain, MD

US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?

Feb 13^th • 5 mins read

Gracy Crane, John C. W. Lim, Churn-Shiouh Gau, Jipan Xie & Laura Chu

The challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: expert panel recommendations

Jun 28^th • 13 mins read

Bhakti Arondekar, Mei Sheng Duh, Rachel H. Bhak, Maral DerSarkissian, Lynn Huynh, Kelsey Wang, John Wojciehowski, Melody Wu, Bryon Wornson, Alexander Niyazov, George D. Demetri

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application

Jan 1^st • 12 mins read

Diana Brixner, PhD, RPh [email protected], Joseph Biskupiak, PhD, MBA, Gary Oderda, PharmD, MPH, Douglas Burgoyne, PharmD, FAMCP, Daniel C Malone, RPh, PhD, FAMCP, Bhakti Arondekar, PhD, MBA, and Alexander Niyazov, PharmD, RPh, MPH

Payer perceptions of the use of real-world evidence in oncology-based decision making

Aug 1^st • 12 mins read

Marc Clausen MA, Chloe Mighton MS, Ruhi Kiflen MPH, Agnes Sebastian MSc, Wei Fang Dai MPH, Rebecca E. Mercer PhD, Jaclyn M. Beca MSc, Wanrudee Isaranuwatchai PhD, Kelvin K.W. Chan MD PhD, Yvonne Bombard PhD

Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders’ perspectives

Nov 4^th • 12 mins read

Bruce A. Feinberg, DO Ajeet Gajra, MBBS, MD Marjorie E. Zettler, PhD, MPH Todd D. Phillips, PharmD Eli G. Phillips Jr., PharmD, JD Jonathan K. Kish, PhD, MPH

Use of Real-World Evidence to Support FDA Approval of Oncology Drugs

Sep 14^th • 16 mins read

Navigation

Results for 'post traumatic stress disorder'

Accelerated drug approvals in oncology: Pros and cons

“Oncometabolism: The switchboard of cancer: An editorial”

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Comment on: Oncology research in Saudi Arabia over a 10-year period. A synopsis

Patient burden and clinical advances associated with post approval monotherapy cancer drug trials: a retrospective cohort study

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

New Realities of Phase I Clinical Trials in the Era of

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration

How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer

Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

Medical affairs: The power behind redefining commercialization

Empowering people to drive medical affairs performance with AI

The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks

US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?

The challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: expert panel recommendations

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application

Payer perceptions of the use of real-world evidence in oncology-based decision making

Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders’ perspectives

Use of Real-World Evidence to Support FDA Approval of Oncology Drugs

Related Topics